Global Payments faces industry pricing pressure

On Monday, November 9th, 2026, Clover Health presented its business at the UBS Global Healthcare Conference. The company highlighted strong growth and increasing earnings power, while acknowledging higher outpatient costs as a challenge. Chief Financial Officer Clay Thornton emphasized the company's focus on expanding earnings alongside maintaining its market-leading membership growth.

Clover reported $97 million of adjusted EBITDA and $62 million of net income year-to-date through the third quarter of 2026. Membership increased by approximately 50% year-over-year, and operating cash flow for 2026 surpassed $200 million.

Medical trends were better than expected in inpatient care and Part D, while outpatient utilization was higher than anticipated. The company expects a significant growth opportunity in 2027 due to a New Jersey plan exit involving around 40,000 Medicare Advantage members. Clover's AI-driven clinical platform, Clover Assistant, received a five-star rating and is expected to support future growth and margin expansion.

Thornton noted that the company's balance sheet offers financial flexibility to fund regulatory capital needs, invest in technology, and support continued membership growth.

Management stated that they have not set a long-term margin target due to the company's ongoing high-growth phase. Clover's market capitalization stands at $2.7 billion, and it experienced 55% revenue growth over the past twelve months. InvestingPro Tips highlight that the company holds more cash than debt on its balance sheet and has been profitable throughout the past year, reinforcing the management's commentary on financial strength.

Clover mentioned the favorable medical trends, with inpatient utilization improving across all member cohorts and new-member cohorts trending lower than the prior year's first-year cohort. Part D trends were also lighter than expected, particularly in the non-low-income population.

The company is focusing on two cost levers: expanding Clover Assistant coverage and tightening provider payment integrity operations. Clover Assistant is considered the company's main competitive advantage, used through in-network physicians and an employed clinician model where about two-thirds of members currently interact with clinicians.

The company's New Jersey business demonstrates the importance of Clover Assistant, as it has ranked No. 1 in the country for PPO plans for three consecutive years. Clover secured a five-star rating on its largest contract, which grants year-round marketing rights and access to a special enrollment period, expected to drive incremental enrollments.

In 2027, the company plans to transfer its pharmacy benefit management business from Caremark to Optum Rx, reflecting a proactive approach to cost control and star ratings after the Inflation Reduction Act altered the economics of Medicare Advantage plans. Clover's stock delivered a 105% year-to-date return and an 81% gain over the past year, with InvestingPro assigning the company a "GREAT" Financial Health score of 3.25 out of 5.